Dizal -J.P. Morgan 44th Annual Healthcare Conference - Dizal Presentation_unlocked.pdf

1、1Xiaolin Zhang,Ph.D.,Chairman and CEOJanuary 15,2026J.P.Morgan Healthcare ConferenceJ.P.Morgan Healthcare Conference2 Dizal Pharmaceutical.All rights reserved.Dizal:A Commercial Stage China Based Biopharmaceutical CompanyMarket Cap:$4BA spin-off of AstraZeneca Innovative Medicine and Early Developme

2、nt AsiaKey disease areas include lung cancer and hematological diseasesClinical DevelopmentCMCCommercial-izationDiscoveryCommercialmanufactureFully integrated capabilities:discovery,development and commercialization Two drugs approved in ChinaOne drug approved in the US,one NDA submission pendingSev

3、en candidates under global clinical development1000 employees in China with 300 in R&D23 Dizal Pharmaceutical.All rights reserved.Highlights of Dizals PipelineProgramTargetMost Advanced StageOngoing/Planned StudiesRecognitionsSunvozertinibEGFR Approved in US and China for r/r NSCLC with EGFR Exon20i

4、ns Ph3 1L EGFR Exon20ins NSCLC Ph3 1L EGFR PACC NSCLC Ph3 Adjuvant EGFR Exon20ins/EGFR PACC NSCLC PoC 1L EGFRm NSCLC in combination with DZD6008 FDA and NMPA Breakthrough Therapy Designation for EGFR Exon20ins NSCLCGolidocitinibJAK1 Approved in China for r/r PTCL Ph3 1L NSCLC with PD-1 Ph3 1L PTCL P

5、oC in ITP FDA Fast Track Designation for PTCL FDA Orphan Drug Designation for T-cell lymphomaDZD60084th Gen EGFRiEGFR Proof-of-Concept PoC EGFRm NSCLC PoC 2L/2L+EGFRm NSCLC in combination with Chemo PoC 1L EGFRm NSCLC in combination with sunvozertinibGW5282EZH1/2 Proof-of-Concept PoC in multiple sol

6、id tumors PoC in hematological malignancesBirelentinib(DZD8586)Lyn/BTK Ph3 pivotal in r/r CLL/SLL Ph3 r/r CLL/SLL Ph3 DLBCL PoC ITP FDA Fast Track Designation for CLL/SLL FDA Orphan Drug Designation for CNSL34 Dizal Pharmaceutical.All rights reserved.ZEGFROVY（Sunvozertinib，DZD9008）Status:Approved in